Get the Stockscreener App
6.01
1.48%
-0.09
After Hours:
6.05
0.04
+0.67%
Clene Inc stock is traded at $6.01, with a volume of 40,785.
It is down -1.48% in the last 24 hours and up +10.28% over the past month.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
See More
Previous Close:
$6.10
Open:
$6.07
24h Volume:
40,785
Relative Volume:
0.09
Market Cap:
$76.80M
Revenue:
$134.00K
Net Income/Loss:
$-33.51M
P/E Ratio:
-1.8738
EPS:
-3.2074
Net Cash Flow:
$-18.15M
1W Performance:
-5.13%
1M Performance:
+10.28%
6M Performance:
-2.12%
1Y Performance:
+54.10%
1-Day Range:
$5.96
$6.23
1-Week Range:
$5.96
$6.4219
52-Week Range:
$3.25
$13.50
Clene Inc Stock (CLNN) Company Profile
Name
Clene Inc
Sector
Industry
Phone
801-676-9695
Address
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Compare CLNN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
6.01 | 78.65M | 134.00K | -33.51M | -18.15M | -3.2074 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-18-22 | Initiated | H.C. Wainwright | Buy |
| May-02-22 | Initiated | Canaccord Genuity | Buy |
| Sep-28-21 | Initiated | Oppenheimer | Outperform |
Clene Inc Stock (CLNN) Latest News
Clene Inc.(NasdaqCM: CLNN) added to Russell Microcap Value Benchmark Index - marketscreener.com
Clene Inc.(NasdaqCM: CLNN) added to Russell Microcap Index - marketscreener.com
CLNN Stock Rises 8% – Here’s What The FDA Update Means For Clene’s ALS Treatment - Stocktwits
Enterprise value to EBITDA forward of Clene Inc. – NASDAQ:CLNN - TradingView
Price to earnings forward of Clene Inc. – NASDAQ:CLNN - TradingView
Price to earnings forward of Clene Inc. – BOATS:CLNN - TradingView
Clene Inc Actuals & Estimates (NASDAQ:CLNN) - TradingView
Enterprise value to EBITDA forward of Clene Inc. – BOATS:CLNN - TradingView
Enterprise value to EBIT forward of Clene Inc. – BOATS:CLNN - TradingView
Enterprise value to revenue forward of Clene Inc. – BOATS:CLNN - TradingView
CLNN Forecast — Price Target — Prediction for 2027 - TradingView
Clene Inc. (CLNN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Clene Inc. (CLNN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CLNN Q1 2026 Earnings: Clinical-Stage Biotech Delivers Narrower-Than-Expected Loss Despite No RevenueROA Comparison - dars.gov.et
Clene Inc. (CLNN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Clene Inc. (CLNNW) Institutional Confidence - TradingKey
Clene Inc. (CLNNW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Clene Inc. (CLNNW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Clene Inc. (CLNNW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Clene Inc. (CLNNW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Clene Inc. (CLNNW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year? - Yahoo Finance
Clene Inc. (CLNN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Clene Inc. (CLNNW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Clene Inc. (CLNN) Institutional Confidence - TradingKey
Clene Inc. (CLNN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Clene Inc. (CLNNW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Clene Inc. (CLNNW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Clene Inc. (CLNN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Clene Inc. (CLNN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Clene Inc. (CLNN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Clene (CLNN) Chief Science Officer receives 45,000-share stock option grant - Stock Titan
Clene (CLNN) CEO receives 65,000 stock options at $5.53 exercise price - Stock Titan
Clene (CLNN) grants CFO 15,000 stock options at $5.53 strike - Stock Titan
Clene Inc. (CLNN) Gains 5.6% as Shares Approach Key ResistanceOversold Bounce Ideas - newsline.com
Clene stock jumps after FDA opens door to accelerated approval for ALS drug - MSN
TruckMountForums acquires Bane-Clene Corporation, uniting two fam - The National Law Review
TruckMountForums acquires Bane-Clene Corporation, uniting two family-owned pillars of the professional - EIN News
Clene (CLNN) may find a bottom soon, here's why you should buy the stock now - MSN
CLNN Q1 2026 Earnings: EPS Beats Expectations Amid No Revenue, Stock DeclinesOne-Time Loss Impact - newsline.com
Clene (CLNN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
CLNN Q1 2026 Earnings: EPS Surprises to the Upside as Company Focuses on Clinical MilestonesBasic EPS Analysis - dars.gov.et
CLNN Q1 2026 Earnings: Significant EPS Beat But Stock SlidesSpecial Dividend Alert - newsline.com
CLNNClene Inc Stock Price and Quote - Finviz
CLNN Technical Analysis & Stock Price Forecast - Intellectia AI
Clene Inc. (CLNN) Shares Slide 2.24% as Stock Tests Key Support LevelsThrowback Trade - thelegaladvocate.com
CLNN Q1 2026 Earnings: EPS Beat Driven by Cost Control Amid No RevenueTangible Book Value - newsline.com
CLNN stock falls after Roth labels accelerated approval for ALS drug a 'long shot' - MSN
CLNN stock rises 8% – here’s what the FDA update means for Clene’s ALS treatment - MSN
Clene Inc. Files Form 8-K with SEC Detailing Company Information and Common Stock Listing on NASDAQ - Minichart
Clene extends note maturity and amends stock plan following annual meeting - Investing.com
Clene Inc Stock (CLNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Clene Inc Stock (CLNN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ugwumba Chidozie | 10% Owner |
May 11 '26 |
Sale |
6.75 |
22,177 |
149,695 |
176,713 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):